The VICC GI SPORE represents the culmination of 12 laboratories working together closely and effectively with clinical investigators over many years with a keen focus on translational research designed to make a profound impact on the prevention, early detection, diagnosis and treatment of CRC. Vanderbilt is known for its highly collaborative environment and unique shared resources. These advantages allow us to swiftly move basic discoveries in the lab from the hands of bench scientists to those of clinical investigators, thus propelling forward innovative approaches to the diagnosis and treatment of colorectal neoplasia.
The goal of the GI SPORE is to apply the translational research strengths of Vanderbilt University toward reducing the incidence, morbidity and mortality of colorectal cancer.
Specifically, our SPORE projects will:
- Provide insight into tumor progression and response to targeted therapeutics
Advance the development of safe and effective CRC drugs
Identify novel prognostic biomarkers
Develop a model to predict risk of adenoma recurrence
Accelerate differential precision therapies and strategies
Together, these advances will reduce deaths from CRC by providing new clinical tools to identify at-risk individuals, early detection of colorectal neoplasia, more accurate disease prognosis, and recognition of cancers with high or low metastatic potential. In short, they will help transform how we diagnose and treat individuals with CRC.
The SPORE in GI Cancer Team
Robert J. Coffey, M.D., Program Director
Jordan D. Berlin, M.D.
R. Daniel Beauchamp, M.D.
Stephen Fesik, Ph.D.
Daniel C. Liebler, Ph.D.
H. Charles Manning, Ph.D.
Harvey J. Murff, M.D., MPH
Yu Shyr, Ph.D.
M. Kay Washington, M.D., Ph.D.
Wei Zheng, M.D., MPH, Ph.D.
For more information about the SPORE program, see NCI's SPORE website.